ChemoCentryx (ChemoCentryx) Stock Based Compensation : $32.48 Mil (TTM As of Jun. 2022)

View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Stock Based Compensation?

ChemoCentryx's Stock Based Compensation for the three months ended in Jun. 2022 was $8.14 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2022 was $32.48 Mil.

ChemoCentryx Stock Based Compensation Historical Data

The historical data trend for ChemoCentryx's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Stock Based Compensation Chart

ChemoCentryx Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Stock Based Compensation

Get a 7-Day Free Trial

8.75

10.83

11.64

22.91

30.69

ChemoCentryx Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Stock Based Compensation	Get a 7-Day Free Trial															7.70	7.42	7.49	9.43	8.14

ChemoCentryx Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.48 Mil.

ChemoCentryx Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

ChemoCentryx (ChemoCentryx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070

Website

https://www.chemocentryx.com

ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Executives

Susan M Kanaya	officer: SVP Finance, CFO & Secretary	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall	director, 10 percent owner, officer: President, CEO and Director	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau	officer: SVP, Finance & Acctg Officer	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt	officer: EVP, Chief Operating Officer	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards	director	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel	officer: CBO and Treasurer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan	officer: Principal Acctg Officer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh	officer: SVP, Research	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027